Darvocet and Darvon Withdrawn from U.S. Market Due to Risk of Abnormal Heart Activity

more+
less-

The drug propoxyphone – marketed and sold as Darvocet and Darvon – was recently withdrawn from the U.S. market by its manufacturer, Xanodyne Pharmaceuticals, at the request of the U.S. Food and Drug Administration (FDA). The drug, which is an opioid pain reliever used to treat mild to moderate pain, was originally approved by the FDA more than 50 years ago, in 1957, but new data has shown that it can cause serious toxicity to the heart, even when used at recommended doses.

The FDA requested that the drug be removed from the U.S. market by Xanodyne Pharmaceuticals and the drug’s generic manufacturers after reaching the conclusion that the risks of the injury outweigh the drug’s pain relief benefits at its current prescribed doses.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Howard Ankin | Attorney Advertising

Written by:

more+
less-

Howard Ankin on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×